Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System

Company Announcements - Accuray Incorporated announced the approval of its Radixact SynC™ System and CyberKnife® S7™ System by the Chinese National Medical Products Administration (NMPA), enabling the provision of advanced radiation therapy solutions in China [9] - The CyberKnife S7 System is the latest generation CyberKnife platform, and the Radixact SynC System marks the first approval in China for ClearRT® kVCT imaging and Synchrony® real-time adaptive delivery technology on the Radixact System [9] Product Innovations - The Radixact SynC System features a helical design that delivers precise radiation doses continuously from multiple 360-degree rotations around the patient, minimizing dose to healthy tissue [4] - ClearRT is a helical kVCT fan-beam integrated imaging solution for the Radixact System, providing diagnostic-like quality CT images for high confidence in patient set-up and registration steps [5] - The CyberKnife S7 System delivers ultra-hypofractionated radiation therapy, completing treatments in 1 to 5 outpatient sessions compared to conventional 30-40 sessions, benefiting patients unable to travel for extended periods [6] - The CyberKnife S7 System is a robotic, non-invasive radiosurgery device capable of treating tumors with sub-millimetric accuracy in as little as 15 minutes, enabling precise radiation treatments for more patients daily [12] Market Strategy and Growth - The company aims to expand patient access in China by offering unique solutions, addressing the significant demand for radiotherapy treatments, with an estimated need for approximately 2,000 systems over the next five years [10] - The Radixact SynC System is the only helical delivery device in China with Synchrony real-time target tracking and correction technology, enhancing precision for tumors affected by bodily processes or patient movement [11] Leadership and Vision - Suzanne Winter, president and CEO of Accuray, expressed enthusiasm about the timing of the approvals, highlighting the introduction of the Tomo C System and the potential to address the needs of the largest market segment in China [3] - The company is dedicated to continuous innovation in radiation therapy for oncology and neuro-radiosurgery, partnering with clinicians to empower patients to return to their lives faster [7]